STOCK TITAN

Biotricity Reports Second Quarter Fiscal 2027 Results

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Biotricity (BTCY) reported 11.5% year-over-year revenue growth for its second quarter of fiscal 2027, ended September 30, 2026. Revenue reached $4.33 million. Gross margin rose to 83.3% from 81.9%, and operating income rose 23.7% to $339 thousand. Operating expenses rose 12.5% to $3.27 million. The net loss attributable to common stockholders widened to $0.95 million from $0.77 million, or $0.046 per share versus $0.029.

Six-month revenue rose 11.0% to $8.61 million, and operating cash flow rose to $511 thousand from $42 thousand. Biotricity signed a national distribution agreement contingent on a successful pilot. Its partner will fund commercial expansion in exchange for a 30% distribution margin. Biotricity was selected for a charitably funded cardiac screening program that will pay in advance at standard commercial rates. It also established long-term inventory financing to fund production.

Loading...
Loading translation...
14 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointQuarterly revenue rose 11.5% year over year to $4.33 million
  • Moderate pointQuarterly operating income rose 23.7% year over year to $339 thousand; operating margin rose to 7.8% from 7.0%
  • Moderate pointSix-month operating cash flow rose to $511 thousand from $42 thousand a year earlier
  • Moderate point. Forward-looking: it has not happened yet and may not happen.National distribution agreement provides for partner-funded commercial expansion if the pilot succeeds
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cardiac screening program will pay Biotricity in advance at its standard commercial rates
  • Moderate pointLong-term inventory financing was established to fund production
8 minor points
  • Minor pointQuarterly technology fee revenue rose 13.3% year over year to $3.98 million, or 91.8% of revenue versus 90.4%
  • Minor pointQuarterly gross margin rose to 83.3% from 81.9% a year earlier
  • Minor pointQuarterly gross profit rose 13.4% year over year to $3.61 million
  • Minor pointQuarterly technology fee gross margin rose to 85.5% from 82.3% a year earlier
  • Minor pointSix-month revenue rose 11.0% year over year to $8.61 million
  • Minor pointSix-month technology fee revenue rose 18.3% year over year
  • Minor pointSix-month gross margin rose to 82.9% from 81.2% a year earlier
  • Minor point. Forward-looking: it has not happened yet and may not happen.Screening device deployment is expected by Biotricity to involve at least 1,000 devices

Negative

  • Moderate pointQuarterly loss attributable to common stockholders widened to $0.95 million, or $0.046 per share, from $0.77 million, or $0.029, a year earlier
  • Moderate pointQuarterly research and development expenses rose 46.7% year over year to $0.88 million
  • Moderate point. Forward-looking: it has not happened yet and may not happen.National distribution rollout requires a successful 18-month pilot limited to 6 states
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Distribution partner will receive a 30% distribution margin in exchange for funding commercial expansion
  • Minor pointSix-month loss attributable to common stockholders widened to $2.02 million, or $0.092 per share, from $1.53 million, or $0.057, a year earlier
5 minor points
  • Minor pointQuarterly net loss before dividends widened to $0.81 million from $0.69 million a year earlier
  • Minor pointSix-month net loss before dividends widened to $1.77 million from $1.36 million a year earlier
  • Minor pointQuarterly selling, general and administrative expenses rose 3.5% year over year
  • Minor pointQuarterly derivative liability revaluation resulted in a $151 thousand non-cash loss
  • Minor point. Forward-looking: it has not happened yet and may not happen.Cardiac screening deployment has no assured timing or extent, and the revenue ultimately recognized is uncertain

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Revenue up 11.5%, gross margin 83.3% and income from operations up 23.7%. 

REDWOOD CITY, CA , Nov. 20, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) ("Biotricity" or the "Company"), a medical technology company providing remote cardiac monitoring solutions, announced its financial results for the second quarter of fiscal 2027, ended September 30, 2026.

Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, said, "Our second quarter delivered year-over-year growth in technology fee revenue, a higher gross margin and operating leverage. Revenue grew 11.5%, gross margin expanded to 83.3% and income from operations rose 23.7%, as gross profit growth outpaced higher operating expenses, including the timing of research and development activities."

Second Quarter Fiscal 2027 Highlights (compared to the second quarter of fiscal 2026)

  • Revenue increased 11.5% to $4.33 million. Technology fee revenue, the majority of which is recurring, increased 13.3% to $3.98 million, or 91.8% of total revenue (prior-year quarter: 90.4%).
  • Gross margin improved to 83.3% from 81.9%, driven by technology fee gross margin of 85.5% (prior-year quarter: 82.3%). Gross profit increased 13.4% to $3.61 million.
  • Operating expenses increased 12.5% to $3.27 million, primarily due to a 46.7% increase in research and development expenses to $0.88 million; selling, general and administrative expenses increased 3.5% from increased sales. Income from operations increased 23.7% to $339 thousand, an operating margin of 7.8% (prior-year quarter: 7.0%).
  • Net loss before dividends was $0.81 million (prior-year quarter: $0.69 million), including a $151 thousand non-cash loss on the change in fair value of derivative liabilities. Net loss attributable to common stockholders was $0.95 million, or $(0.046) per share, compared to $0.77 million, or $(0.029) per share, on fewer weighted average shares.

Six-Month Highlights (compared to the prior-year period)

  • Revenue increased 11.0% to $8.61 million, driven by an 18.3% increase in technology fee revenue. Gross margin improved to 82.9% from 81.2%.
  • Net loss before dividends was $1.77 million (prior-year period: $1.36 million). Net loss attributable to common stockholders was $2.02 million, or $(0.092) per share, compared to $1.53 million, or $(0.057) per share.
  • Net cash provided by operating activities was $511 thousand (prior-year period: $42 thousand), primarily reflecting higher accounts payable, accrued liabilities and collections of accounts receivable.

Corporate Developments

  • The Company signed a national distribution agreement, subject to a successful pilot program, where the partner will fund commercial expansion in exchange for a 30% distribution margin. The 18-month pilot was officially kicked off in October and is restricted to 6 states. Upon a successful pilot, the program will be expanded.
  • In October 2026, the Company was selected to provide cardiac screenings to patients in low-income communities and developing countries under a charitably funded program. The Company will be paid in advance at its standard commercial rates and currently expects the program to involve the deployment of at least 1,000 devices; there can be no assurance as to the timing or extent of deployment or the revenue ultimately recognized.
  • Successfully established a long-term inventory financing program to fund production.

Full results are included in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 16, 2026 with the U.S. Securities and Exchange Commission and available at www.sec.gov.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic cardiac care. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for cardiac conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements, which can generally be identified by words such as "may," "will," "expect," "anticipate," "estimate," "believe," "intend," "plan," "seek" and similar expressions. These include statements regarding expected growth in technology fee revenue, gross margin and operating efficiency; the scope and timing of the cardiac screening program and related device deployment; the refinancing of the Company's term loan; and further forbearance from its term lender. These statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially, including: the Company's ability to continue as a going concern; its ability to refinance its term loan or obtain further forbearance, and the lender's ability to terminate the forbearance and accelerate the term loan; dilution from warrants issuable to the lender if the refinancing is not completed by December 31, 2026; the timing and extent of device deployment and revenue recognition under the cardiac screening program, the continued availability of charitable funding and any foreign regulatory authorizations required to deploy devices outside the United States; seasonality and concentration of revenue in technology fees; its ability to obtain additional financing; the time and resources required to develop its products; government regulation of medical devices and the healthcare industry; competition; and the volatility and limited liquidity of its stock. These and other factors are described in the Company's filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Contacts

Investor Relations
Biotricity Investor Relations
Investors@biotricity.com

SOURCE: Biotricity Inc.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Biotricity's revenue and operating income grow in fiscal Q2 2027?

Biotricity's quarterly revenue rose 11.5% to $4.33 million, and operating income rose 23.7% to $339 thousand from a year earlier. Operating margin increased to 7.8% from 7.0%.

What drove Biotricity's higher operating cash flow in the first six months of fiscal 2027?

Biotricity said the increase primarily reflected higher accounts payable, accrued liabilities and collections of accounts receivable. Operating activities provided $511 thousand in cash, compared with $42 thousand a year earlier.

How long is Biotricity's national distribution pilot and where can it operate?

Biotricity's pilot runs for 18 months and is limited to 6 states. It began in October, and the program will expand if the pilot succeeds.

How many devices does Biotricity expect to deploy through its cardiac screening program?

Biotricity expects the program to involve at least 1,000 devices. The timing and extent of deployment and the revenue ultimately recognized are not assured.

Keep reading